Form 4: Supernus CEO Exercises Options, Sells Shares

Supernus Pharmaceuticals CEO Jack A. Khattar exercised stock options and sold a portion of his shares under a pre-arranged 10b5-1 trading plan.

Summary

• Jack A. Khattar, President, CEO, and Director of Supernus Pharmaceuticals, Inc. (SUPN), engaged in two transactions on August 22, 2025.
• Khattar acquired 2,415 shares of Common Stock by exercising employee stock options at a price of $12.98 per share.
• Following the option exercise, Khattar's direct beneficial ownership of Common Stock was 1,072,348 shares.
• Subsequently, Khattar sold 1,500 shares of Common Stock at a weighted average price of $45.00 per share, with prices ranging from $45.00 to $45.01.
• Both transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.
• After these transactions, Khattar's direct beneficial ownership of Common Stock stands at 1,070,848 shares.
• Additionally, Khattar indirectly beneficially owns 1,005,600 shares of Common Stock through The KBT Trust, bringing his total beneficial ownership to 2,076,448 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine disclosure of insider transactions (option exercise and sale) executed under a pre-arranged 10b5-1 plan. It does not provide new fundamental information about the company's performance or strategic direction.

Positives

• The sale price of $45.00 per share is significantly higher than the option exercise price of $12.98 per share, indicating a profitable transaction for the insider.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which demonstrates a structured approach to managing stock holdings and reduces concerns about opportunistic selling.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by the market, although the impact is typically mitigated by the existence of a 10b5-1 plan.

Future Outlook

This Form 4 filing reports past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• The transactions were made pursuant to a 10b5-1 trading plan adopted November 14, 2024.
• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4, upon request.

Industry Context

Insider transaction reports (Form 4s) are standard disclosures for publicly traded companies. The use of a 10b5-1 trading plan is a common practice among corporate insiders to manage their equity holdings in compliance with insider trading regulations, allowing them to sell shares at pre-determined times or prices without being accused of trading on material non-public information.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even if pre-planned, could be viewed with slight caution, but the relatively small volume and the 10b5-1 plan mitigate significant negative impact. The profitable exercise of options indicates the executive's long-term incentive alignment.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 reports routine insider transactions (option exercise and subsequent sale) executed under a pre-arranged 10b5-1 trading plan. It does not provide new fundamental information about Supernus Pharmaceuticals' operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transactions are a standard part of executive compensation and personal financial planning, and therefore, a 'hold' recommendation is appropriate as no new material information affecting the company's valuation has been disclosed.

Keywords

Supernus Pharmaceuticals, SUPN, Jack A. Khattar, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Pharmaceuticals, Biotech